WallStreetZenWallStreetZen

NASDAQ: JAZZ
Jazz Pharmaceuticals Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Jazz Pharmaceuticals revenue was $4.16B for the trailing 12 months ending Sep 30, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q3 2025) ending on Sep 30, 2025 was $1.1B, up 7.7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, JAZZ annual revenue was $4.1B, with 6.1% growth year-over-year.

JAZZ past revenue growth

How has JAZZ's revenue growth performed historically?

Company
4.14%
Industry
141.99%
Market
21.02%
JAZZ's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
JAZZ's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
JAZZ's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

JAZZ revenue history

Current Revenue
$4.2B
Current Earnings
-$368.5M
Current Profit Margin
-8.9%

Be the first to know when JAZZ announces revenue.

JAZZ Revenue History By Year

JAZZ Yearly RevenueJAZZ RevenueJAZZ ChangeJAZZ Revenue Growth
2024-12-31$4.07B$234.75M+6.12%
2023-12-31$3.83B$174.83M+4.78%
2022-12-31$3.66B$565.14M+18.26%
2021-12-31$3.09B$730.67M+30.91%
2020-12-31$2.36B$201.81M+9.34%
2019-12-31$2.16B$270.84M+14.32%
2018-12-31$1.89B$272.23M+16.82%
2017-12-31$1.62B$130.72M+8.79%
2016-12-31$1.49B$163.17M+12.32%
2015-12-31$1.32B$151.93M+12.95%
2014-12-31$1.17B$300.45M+34.44%
2013-12-31$872.42M$286.44M+48.88%
2012-12-31$585.98M$313.70M+115.21%
2011-12-31$272.28M$98.50M+56.68%
2010-12-31$173.78M$45.33M+35.29%
2009-12-31$128.45M$60.94M+90.26%
2008-12-31$67.51M$2.21M+3.39%
2007-12-31$65.30M$20.45M+45.58%
2006-12-31$44.86M$23.41M+109.20%
2005-12-31$21.44MN/AN/A
2004-12-31$0.00N/AN/A

1 of 2

Jazz Pharmaceuticals Revenue FAQ

What was JAZZ's revenue last quarter?

On Invalid Date, Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 2025 revenue of $1.13 billion up 6.74% year over year. In the same quarter last year, Jazz Pharmaceuticals's revenue was $1.05 billion.

What was Jazz Pharmaceuticals's revenue in 2024?

Jazz Pharmaceuticals's annual revenue for the twelve months ending Dec 31, 2024 was $4.07 billion, a 6.12% increase year over year.

How much does Jazz Pharmaceuticals make in a day?

Based on Jazz Pharmaceuticals annual revenue for the past five years, JAZZ makes an average of $9,326,209.86 per day.

What was Jazz Pharmaceuticals's annual revenue growth in the past year?

As of Q4 2025, Jazz Pharmaceuticals's revenue has grown 4.14% year over year. This is 137.85 percentage points lower than the US Biotechnology industry revenue growth rate of 141.99%. Jazz Pharmaceuticals's revenue in the past year totaled $4.16 billion.

How much does Jazz Pharmaceuticals make in a year?

Jazz Pharmaceuticals's revenue by year for the past five years is:
  • Jazz Pharmaceuticals's revenue for the twelve months ending Dec 31, 2024 was $4.07 billion, a 6.12% increase year over year.
  • Jazz Pharmaceuticals's annual revenue for Dec 31, 2023 was $3.83 billion, a 4.78% increase from 2022.
  • Jazz Pharmaceuticals's annual revenue for 2022 was $3.66 billion, a 18.26% increase from 2021.
  • Jazz Pharmaceuticals's annual revenue for 2021 was $3.09 billion, a 30.91% increase from 2020.
  • Jazz Pharmaceuticals's annual revenue for 2020 was $2.36 billion, a 9.34% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.